This is the AGAVE-201 trial [NCT04710576]. It was a phase 2 randomized trial, and they looked at 3 different dosing schedules ...

Over 150 oncologists choose their preference for combination regimens in metastatic ccRCC based on current data in the ...

A study compares second-look laparoscopy and circulating tumor DNA (ctDNA) to detect residual ovarian cancer and predict ...

Innovent's bispecific antibody, IBI363, enters a global phase 3 trial for IO-resistant lung cancer, the first of its kind, ...

Shifting from a tumor-centric to a patient-centric approach is key for older cancer patients, focusing on functional capacity ...

Dordaviprone received accelerated FDA approval for H3 K27M-mutant diffuse midline glioma, an aggressive brain tumor, making ...

A trade agreement between the US and EU sets a 15% tariff on most European pharma imports, impacting oncology drug supplies ...

Welcome to this week's edition of The Targeted Pulse, your clinical-focused wrap-up of the most impactful news and research ...

An MD Anderson team led by Amir Jazaeri, MD, takes a pioneering approach to finding residual ovarian cancer cells.

Robert L. Ferris, MD, PhD, editor-in-chief of Targeted Therapies in Oncology, discusses his monthly column in this episode of ...

A new study suggests the MAGIC Composite Response metric, which combines clinical and biomarker data, improves prediction of ...

A study shows talquetamab is a safe, effective bridge for high-risk patients, potentially improving outcomes and mitigating ...